Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bioxcel Therapeutics ( (BTAI) ) has shared an update.
On February 4, 2026, BioXcel Therapeutics entered into milestone and retention bonus agreements with key employees, including senior management, tied to its recent supplemental New Drug Application to the U.S. FDA for IGALMI for at-home treatment of agitation in bipolar disorder and schizophrenia. The agreements provide cash bonuses of $225,000 per employee, with $150,000 paid upfront and $75,000 due on April 15, 2026, while the CEO’s total bonus is $650,000, contingent on continued employment, the absence or cure of defaults under the company’s credit agreement, and possible acceleration if the company raises at least $25 million or completes a change-of-control or other material transaction, with clawback provisions if employees depart under specified adverse circumstances before late 2026, underscoring a strong focus on retaining leadership during a pivotal regulatory and financing period.
The most recent analyst rating on (BTAI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Bioxcel Therapeutics stock, see the BTAI Stock Forecast page.
Spark’s Take on BTAI Stock
According to Spark, TipRanks’ AI Analyst, BTAI is a Neutral.
The score is held down primarily by very weak financial performance (ongoing large losses, heavy cash burn, negative equity and high debt). Technical indicators are mixed and do not confirm a strong uptrend, while valuation lacks support due to negative earnings and no dividend. Offsetting factors include constructive corporate catalysts around IGALMI’s potential at-home label expansion and supportive clinical data.
To see Spark’s full report on BTAI stock, click here.
More about Bioxcel Therapeutics
BioXcel Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for neuropsychiatric conditions, including agitation associated with bipolar disorders and schizophrenia, with its IGALMI product targeting both inpatient and at-home (outpatient) settings in the U.S. market.
Average Trading Volume: 589,245
Technical Sentiment Signal: Sell
Current Market Cap: $32.59M
Find detailed analytics on BTAI stock on TipRanks’ Stock Analysis page.